DK0879056T3 - Modulation af Th1/Th2-cytokinekspression med ribavirin i aktiverede T-lymfocytter - Google Patents

Modulation af Th1/Th2-cytokinekspression med ribavirin i aktiverede T-lymfocytter

Info

Publication number: DK0879056T3
Authority: DK; Denmark
Prior art keywords: activated; ribavirin3; ribavirin; lymphocytes; modulation
Prior art date: 1996-01-23

Application number

DK97904765T

Other languages

Danish (da)

English (en)

Inventor

Robert Tam

Kandsamy Ramasamy

Devron Averett

Original Assignee

Icn Pharmaceuticals

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-01-23

Filing date

1997-01-21

Publication date

2002-08-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26712784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0879056(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-01-23 Priority claimed from US08/590,449 external-priority patent/US5767097A/en

1997-01-21 Application filed by Icn Pharmaceuticals filed Critical Icn Pharmaceuticals

2002-08-19 Application granted granted Critical

2002-08-19 Publication of DK0879056T3 publication Critical patent/DK0879056T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Tropical Medicine & Parasitology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Steroid Compounds (AREA)

DK97904765T 1996-01-23 1997-01-21 Modulation af Th1/Th2-cytokinekspression med ribavirin i aktiverede T-lymfocytter DK0879056T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/590,449 US5767097A (en)	1996-01-23	1996-01-23	Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US3609497P	1997-01-17	1997-01-17
PCT/US1997/000600 WO1997026883A1 (en)	1996-01-23	1997-01-21	Modulation of th1/th2 cytokine expression by ribavirin® and ribavirin® analogs in activated t-lymphocytes

Publications (1)

Publication Number	Publication Date
DK0879056T3 true DK0879056T3 (da)	2002-08-19

Family

ID=26712784

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK97904765T DK0879056T3 (da)	1996-01-23	1997-01-21	Modulation af Th1/Th2-cytokinekspression med ribavirin i aktiverede T-lymfocytter

Country Status (21)

Country	Link
EP (1)	EP0879056B1 (no)
KR (1)	KR100298158B1 (no)
CN (1)	CN1190198C (no)
AT (1)	ATE216886T1 (no)
BR (1)	BR9707154A (no)
CA (1)	CA2246162C (no)
CZ (1)	CZ293584B6 (no)
DE (1)	DE69712316T2 (no)
DK (1)	DK0879056T3 (no)
ES (1)	ES2172764T3 (no)
HU (1)	HU220105B (no)
IL (1)	IL125088A0 (no)
NO (1)	NO983372L (no)
NZ (1)	NZ330784A (no)
PL (1)	PL187439B1 (no)
PT (1)	PT879056E (no)
RU (1)	RU2186569C2 (no)
SI (1)	SI9720013A (no)
SK (1)	SK283342B6 (no)
UA (1)	UA46815C2 (no)
WO (1)	WO1997026883A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1254911A1 (en) *	1996-10-16	2002-11-06	ICN Pharmaceuticals, Inc.	Monocyclic L-nucleosides, analogs and uses thereof
HUP9904665A3 (en)	1996-10-25	2000-11-28	Minnesota Mining And Mfg Co Sa	Immune response modifier compounds for treatment of th2 mediated and related diseases
CA2357735A1 (en) *	1999-01-29	2000-08-03	Icn Pharmaceuticals, Inc.	Modulation of immune response by ribavirin
US7638496B2 (en)	2000-02-15	2009-12-29	Valeant Pharmaceuticals North America	Nucleoside analogs with carboxamidine modified monocyclic base
US6455508B1 (en) *	2000-02-15	2002-09-24	Kanda S. Ramasamy	Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US7022830B2 (en)	2000-08-17	2006-04-04	Tripep Ab	Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en)	2000-08-29	2004-01-20	Tripep Ab	Vaccines containing ribavirin and methods of use thereof
EP1947185B1 (en) *	2000-08-17	2011-07-20	Tripep Ab	HCV NS3/4A encoding nucleic acid
US6858590B2 (en)	2000-08-17	2005-02-22	Tripep Ab	Vaccines containing ribavirin and methods of use thereof
US20030099668A1 (en)	2001-09-14	2003-05-29	Cytos Biotechnology Ag	Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
CA2529311A1 (en) *	2003-03-28	2004-10-07	Pharmasset, Inc.	Compounds for the treatment of flaviviridae infections
US20050182252A1 (en)	2004-02-13	2005-08-18	Reddy K. R.	Novel 2'-C-methyl nucleoside derivatives
JP5484732B2 (ja)	2005-12-14	2014-05-07	サイトスバイオテクノロジーアーゲー	過敏症の治療のための免疫賦活性核酸パッケージ粒子
ZA200806266B (en) *	2006-03-09	2010-05-26	Om Pharma	Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines
MX2008015529A (es)	2006-06-12	2009-01-13	Cytos Biotechnology Ag	Procesos para empacar oligonucleotidos en particulas similares a virus de bacteriofagos de arn.
EP2185195A2 (en)	2007-08-16	2010-05-19	Tripep Ab	Immunogen platform
BR112014014740B1 (pt)	2011-12-22	2021-08-24	Alios Biopharma, Inc	Compostos de nucleosídeos, nucleotídeos e análogos destes, seu uso e composição farmacêutica
USRE48171E1 (en)	2012-03-21	2020-08-25	Janssen Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en)	2012-03-21	2016-09-13	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
ES2597757T3 (es)	2012-05-25	2017-01-20	Janssen Sciences Ireland Uc	Nucleósidos de uracilespirooxetano
CN105073766A (zh)	2012-12-21	2015-11-18	艾丽奥斯生物制药有限公司	取代的核苷、核苷酸及其类似物
AU2014331863C1 (en)	2013-10-11	2019-05-16	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
EP3143404B1 (en)	2014-05-16	2018-08-29	Amgen Inc.	Assay for detecting th1 and th2 cell populations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69232706T2 (de) *	1991-05-01	2002-11-28	Henry M. Jackson Foundation For The Advancement Of Military Medicine, Rockville	Verfahren zur behandlung infektiöser respiratorischer erkrankungen

1997
- 1997-01-21 EP EP97904765A patent/EP0879056B1/en not_active Revoked
- 1997-01-21 KR KR1019980705645A patent/KR100298158B1/ko not_active IP Right Cessation
- 1997-01-21 AT AT97904765T patent/ATE216886T1/de not_active IP Right Cessation
- 1997-01-21 WO PCT/US1997/000600 patent/WO1997026883A1/en active IP Right Grant
- 1997-01-21 CA CA002246162A patent/CA2246162C/en not_active Expired - Lifetime
- 1997-01-21 SI SI9720013A patent/SI9720013A/sl not_active IP Right Cessation
- 1997-01-21 CN CNB971917760A patent/CN1190198C/zh not_active Expired - Fee Related
- 1997-01-21 IL IL12508897A patent/IL125088A0/xx unknown
- 1997-01-21 ES ES97904765T patent/ES2172764T3/es not_active Expired - Lifetime
- 1997-01-21 PT PT97904765T patent/PT879056E/pt unknown
- 1997-01-21 HU HU9900681A patent/HU220105B/hu not_active IP Right Cessation
- 1997-01-21 DK DK97904765T patent/DK0879056T3/da active
- 1997-01-21 NZ NZ330784A patent/NZ330784A/xx unknown
- 1997-01-21 CZ CZ19982329A patent/CZ293584B6/cs not_active IP Right Cessation
- 1997-01-21 UA UA98073815A patent/UA46815C2/uk unknown
- 1997-01-21 DE DE69712316T patent/DE69712316T2/de not_active Revoked
- 1997-01-21 SK SK1004-98A patent/SK283342B6/sk not_active IP Right Cessation
- 1997-01-21 PL PL97328003A patent/PL187439B1/pl not_active IP Right Cessation
- 1997-01-21 RU RU98115594/14A patent/RU2186569C2/ru active
- 1997-01-21 BR BR9707154A patent/BR9707154A/pt not_active Application Discontinuation
1998
- 1998-07-22 NO NO983372A patent/NO983372L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2246162C (en)	2000-04-04
UA46815C2 (uk)	2002-06-17
DE69712316T2 (de)	2003-01-02
ES2172764T3 (es)	2002-10-01
EP0879056B1 (en)	2002-05-02
HUP9900681A2 (hu)	1999-07-28
NO983372D0 (no)	1998-07-22
KR100298158B1 (ko)	2001-09-06
NZ330784A (en)	1999-02-25
IL125088A0 (en)	1999-01-26
PT879056E (pt)	2002-10-31
CZ293584B6 (cs)	2004-06-16
HUP9900681A3 (en)	1999-12-28
EP0879056A1 (en)	1998-11-25
SK100498A3 (en)	2001-03-12
CA2246162A1 (en)	1997-07-31
AU700642B2 (en)	1999-01-14
PL328003A1 (en)	1999-01-04
SK283342B6 (sk)	2003-06-03
WO1997026883A1 (en)	1997-07-31
RU2186569C2 (ru)	2002-08-10
ATE216886T1 (de)	2002-05-15
CN1190198C (zh)	2005-02-23
DE69712316D1 (en)	2002-06-06
PL187439B1 (pl)	2004-07-30
BR9707154A (pt)	1999-05-25
HU220105B (hu)	2001-10-28
SI9720013A (sl)	1999-06-30
NO983372L (no)	1998-09-21
EP0879056A4 (en)	1999-01-13
CN1209747A (zh)	1999-03-03
AU1747897A (en)	1997-08-20
KR19990081930A (ko)	1999-11-15
CZ232998A3 (cs)	1999-04-14

Publication	Publication Date	Title
DK0879056T3 (da)	2002-08-19	Modulation af Th1/Th2-cytokinekspression med ribavirin i aktiverede T-lymfocytter
EP0219076A3 (en)	1988-04-20	Sustained release composition
ATE49126T1 (de)	1990-01-15	Mittel zur transdermalen applikation von arzneistoffen.
DE59007178D1 (de)	1994-10-27	Verwendung alkylierter Polyethylenimine als gallensäureadsorbierende Arzneimittel sowie pharmazeutische Präparate.
DE3677897D1 (de)	1991-04-11	Menschliche komplementfaktoren und ihre therapeutische verwendung.
DE3682457D1 (de)	1991-12-19	Geraet zur verabreichung von medikamenten an patienten.
ES2139574T3 (es)	2000-02-16	Nuevos gases propulsores y su uso en preparaciones medicas.
ATE157251T1 (de)	1997-09-15	Verwendung von inositoltriphosphat zur behandlung von entzündungen
ES8801930A1 (es)	1988-03-16	Procedimiento para la preparacion de dipeptidos de n,n'-dialquilguanidino
BR9814957A (pt)	2000-10-03	Tratamento de doenças imune mediadas por célula auxiliar "t" tipo 2 com antagonistas retinóides
ES290656Y (es)	1986-11-16	Dispositivo para recoger y mantener vivos los cultivos del cuerpo del paciente.
ES2197500T3 (es)	2004-01-01	Uso de cloruro de n,n-bis(fenilcarbamoilmetil)dimetilamonio y sus usos derivados en el tratamiento del dolor cronico.
ES2151607T3 (es)	2001-01-01	Factor 12 de crecimiento y de diferenciacion.
DE59407457D1 (de)	1999-01-21	Blockierung der anlagerung von keimen an menschliche zellen
DK0951553T3 (da)	2004-02-09	Adenovirus-E4-proteiner til induktion af celledød
EP1240899A3 (en)	2004-05-19	Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections
DE3750151D1 (de)	1994-08-04	Verwendung von aktivierten T-Lymphozyten zur Vorbereitung einer pharmazeutischen Zusammensetzung zur Behandlung von AIDS.
ATE84058T1 (de)	1993-01-15	Gel-zusammensetzung.
ES2061496T3 (es)	1994-12-16	Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante.
ES8704903A1 (es)	1987-04-16	Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
DK369886A (da)	1987-02-02	Hidtil ukendte acylphosphotriamider og pharmaceutisk komposition indeholdende samme til aendring af lipidindholdet i blodplasma hospattedyr
EP1174141A3 (en)	2003-04-23	Modulation of TH1/TH2 cytokine expression by ribavirin and ribavirin analogs in activated t-lymphocytes
ATE87207T1 (de)	1993-04-15	Azapropazon zur praevention von post-ischaemischem gewebeschaden.
DK222988A (da)	1988-10-24	Farmaceutiske praeparater indeholdende ornithin-decarboxylase-inhibitorer
ES2026966T3 (es)	1992-05-16	Procedimiento para la obtencion de 4-metil-4-fenil-1-penta--nales y su empleo como perfumantes.